Skip to main content
. 2017 Oct 11;8(61):103207–103222. doi: 10.18632/oncotarget.21732

Figure 3. BRAFV600E and PIK3CAH1047R tumors present a paradoxical activation of ERK under PLX-4720 treatment after 10 weeks.

Figure 3

(A) Representative pooled western blot (left), and quantification of single sample blots (right) of proteins from BRAFV600E/PIK3CAH1047R double mutant mice treated for 70 days with either vehicle, PLX-4720 (30 mg/kg), GDC-0941 (50 mg/kg) or a combination of both. (B) Representative pooled western blot (left), and quantification of single sample blots (right) of proteins from BRAFV600E single mutant mice treated for 76 days with either vehicle or PLX-4720 (30 mg/kg). Error bars represent standard deviation. Values represent means of calculated ratios. Points represent single ratio values.